Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
2.
Vaccine ; 30(34): 5172-8, 2012 Jul 20.
Artículo en Inglés | MEDLINE | ID: mdl-21414380

RESUMEN

Since children with chronic diseases represent a primary target for immunization strategies, it is important that their immunization coverage and timeliness of vaccines is optimal. We performed a study to measure immunization coverage and timeliness of vaccines in children with type 1 diabetes, HIV infection, Down syndrome, cystic fibrosis, and neurological diseases. A total of 275 children aged 6 months-18 years were included in the study. Coverage for diphtheria-tetanus-pertussis (DTP), polio (Pol), and hepatitis B (HBV) vaccines approximated 85% at 24 months, while measles-mumps-rubella (MMR) coverage was 62%. Immunization coverage for seasonal influenza was 59%. The analysis of timeliness revealed that there was heterogeneity among children with different chronic diseases. A proportional hazard model showed that children with HIV infection had the longest time to complete three doses of DTP, Pol, and HBV, and those with neurological diseases received the first dose of MMR later than the other categories. Causes of missing or delayed vaccination mostly included a concurrent acute disease. Children with chronic diseases should be strictly monitored for routine and recommended vaccinations, and health care providers and families should be properly informed to avoid false contraindications.


Asunto(s)
Enfermedad Crónica/prevención & control , Programas de Inmunización/estadística & datos numéricos , Esquemas de Inmunización , Vacunación/estadística & datos numéricos , Adolescente , Niño , Preescolar , Enfermedad Crónica/epidemiología , Control de Enfermedades Transmisibles/métodos , Estudios Transversales , Vacuna contra Difteria, Tétanos y Tos Ferina/administración & dosificación , Femenino , Vacunas contra Hepatitis B/administración & dosificación , Humanos , Programas de Inmunización/normas , Lactante , Vacunas contra la Influenza/administración & dosificación , Gripe Humana/prevención & control , Entrevistas como Asunto , Italia/epidemiología , Masculino , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Vacunación/normas
3.
Gut ; 53(2): 229-34, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14724155

RESUMEN

BACKGROUND AND AIMS: Protease activated receptors (PARs) have been postulated to play a role during intestinal inflammation. The presence and role played by PAR(4) in gastrointestinal functions have not been fully clarified. The aims of this study were: (i) to examine expression of PAR(4) in rat proximal colon; (ii) to determine the mechanical effects induced by PAR(4) activation in longitudinal muscle; and (iii) to characterise the underlying mechanisms. METHODS: PAR(4) expression was determined by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. Mechanical activity was recorded as changes in isometric tension. RESULTS: A PCR product corresponding to the predicted size of the PAR(4) signal was amplified from RNA prepared from the colon of rats, showing the presence of PAR(4) in those tissues. Immunohistochemistry revealed that PAR(4) protein was expressed on epithelial surfaces and submucosa. PAR(4) activating peptides, GYPGKF-NH(2) and AYPGKG-NH(2), produced concentration dependent contractile effects on longitudinal muscle. Tetrodotoxin (TTX) or atropine significantly reduced the contractile responses to AYPGKG-NH(2), and atropine after TTX did not cause any further reduction. NK(1) receptor antagonist, SR140333, or NK(2) receptor antagonist, SR48968, alone or in combination, produced a reduction in PAR(4) induced contractile effect, and when coadministered with TTX abolished it. Capsaicin markedly reduced the contractions evoked by AYPGKG-NH(2). CONCLUSIONS: The present results suggest that PAR(4) is functionally expressed in rat colon and its activation induces contraction of the longitudinal muscle both through TTX sensitive release of acetylcholine and release of tachykinins, probably from sensory nerves. These actions may contribute to motility disturbances during intestinal trauma and inflammation.


Asunto(s)
Colitis/metabolismo , Colon/química , Receptores de Trombina/análisis , Animales , Atropina/farmacología , Benzamidas/farmacología , Capsaicina/farmacología , Colitis/fisiopatología , Colon/fisiopatología , Relación Dosis-Respuesta a Droga , Motilidad Gastrointestinal , Inmunohistoquímica/métodos , Masculino , Contracción Muscular/efectos de los fármacos , Músculo Liso/fisiopatología , Antagonistas del Receptor de Neuroquinina-1 , Oligopéptidos/farmacología , Piperidinas/farmacología , Quinuclidinas/farmacología , ARN Mensajero/análisis , Ratas , Ratas Wistar , Receptores de Neuroquinina-2/antagonistas & inhibidores , Receptores de Trombina/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Tetrodotoxina/farmacología
7.
Ann Ig ; 7(5): 329-38, 1995.
Artículo en Italiano | MEDLINE | ID: mdl-8679174

RESUMEN

Although economic evaluation offers a relevant contribution to the health policy's choices, only few studies appeared so far on its application to the field of vaccinations. The present study compares several hypotheses of vaccination strategies in order to evaluate the opportunity to introduce a vaccination program against Haemophilus influenzae b infection. The vaccination strategies are evaluated in terms of costbenefits, cost-effectiveness and cost-utility. The results show that the highest benefits could be obtained performing mass vaccination in the age-group 0-5 years. Actually this hypothesis, compared to other, offers the best compliance and externalities; furthermore it has the highest ethical value.


Asunto(s)
Infecciones por Haemophilus/prevención & control , Vacunas contra Haemophilus/economía , Haemophilus influenzae , Vacunación/economía , Factores de Edad , Preescolar , Estudios de Cohortes , Análisis Costo-Beneficio , Infecciones por Haemophilus/epidemiología , Humanos , Lactante , Recién Nacido , Italia/epidemiología
8.
Recenti Prog Med ; 85(6): 340-7, 1994 Jun.
Artículo en Italiano | MEDLINE | ID: mdl-8047684

RESUMEN

Visceral leishmaniasis (VL) is a public health problem in most countries bordering the Mediterranean sea. The disease has been found in central and southern Italy, Sicily, Sardinia; some pockets are present in Liguria. Dogs are the reservoirs and the vectors are some species of sandfly (Phlebotomus species). The incubation period is usually between 2 and 8 months; children and adults may become infected; lethality may be high and depends upon a correct diagnosis and treatment. The diagnosis should be suspected on the basis of the epidemiological data and clinical picture and confirmed by the detection of specific antibodies by appropriate techniques. Leishmaniasis can be detected in splenic or bone marrow aspirates. Patients with HIV infection and VL may lack specific antibodies; parasitological diagnosis is mandatory for these patients. Antimonials are the classic therapeutic agents for VL. Recently liposomal amphotericin B (Ambisome) has been successfully used, with negligible toxicity.


Asunto(s)
Leishmaniasis Visceral/epidemiología , Animales , Antiprotozoarios/uso terapéutico , Reservorios de Enfermedades , Perros , Humanos , Insectos Vectores , Italia/epidemiología , Leishmaniasis Visceral/diagnóstico , Leishmaniasis Visceral/tratamiento farmacológico , Leishmaniasis Visceral/transmisión , Phlebotomus , Prevalencia
9.
Epidemiol Infect ; 111(2): 297-306, 1993 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8405156

RESUMEN

Although human visceral leishmaniasis (VL) is a notifiable disease in Italy, there is evidence that the actual number of cases is far higher than that notified. A programme for active surveillance of VL in the 14 Italian endemic regions was launched by the Istituto Superiore di Sanità. We report data collected during a 3-year period of active surveillance in Campania, a south Tyrrhenian region covering 4.5% of the Italian territory. Out of 120 clinically suspected cases referred to medical and diagnostic references centres, there were 52 confirmed VL cases (17.3/year), i.e. 10-fold more than previously notified. Most of the infection sites were in rural areas or peripheral districts of towns in hilly parts of Naples province. An epidemic cluster of 10 cases was identified in a microfocus of Caserta province. The biochemical analysis of 23 Leishmania stocks showed a zymodeme composition indicating Campania as an old and well-established focus of VL. The data obtained emphasize that the present notification system for VL in Italy is inadequate.


Asunto(s)
Isoenzimas/análisis , Leishmania infantum/enzimología , Leishmaniasis Visceral/epidemiología , Vigilancia de la Población , Adolescente , Adulto , Alopurinol/uso terapéutico , Animales , Antiprotozoarios/uso terapéutico , Niño , Preescolar , Brotes de Enfermedades , Femenino , Humanos , Lactante , Recién Nacido , Italia/epidemiología , Leishmaniasis Visceral/diagnóstico , Leishmaniasis Visceral/tratamiento farmacológico , Masculino , Meglumina/uso terapéutico , Antimoniato de Meglumina , Compuestos Organometálicos/uso terapéutico , Estaciones del Año , Pruebas Cutáneas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA